Abstract
External beam radiation therapy is a standard treatment for prostate cancer (PCa), but acquired radioresistance often limits its efficacy. This study investigates the role of the tumor suppressor gene DAB2IP in this process. Preliminary results indicated that loss of DAB2IP expression leads to resistance to γ-rays. By fractionally irradiating PCa cells, researchers observed a continuous reduction in DAB2IP mRNA levels alongside increased ATM expression. While α-particles were generally more effective than γ-rays, DAB2IP-deficient cells remained resistant to high-LET radiation. These findings suggest that radiotherapy-induced DAB2IP downregulation contributes to acquired radioresistance in PCa patients.
Introduction
Radiotherapy is a cornerstone of prostate cancer management, yet many patients develop resistance over time. A key player in aggressive PCa is DAB2IP (Disabled homolog 2 interactive protein), a tumor suppressor often absent in aggressive, metastatic cases. This study addresses whether standard clinical practice—fractionated radiation—actually causes the loss of DAB2IP and if such loss can be overcome by high-Linear Energy Transfer (LET) radiation, specifically α-particles.
Methods
The researchers utilized the PC3 human prostate cancer cell line, creating a DAB2IP-deficient model (shDAB2IP) via shRNA-lentiviral knockdown. A fractionated irradiation protocol was designed to mimic clinical schedules, involving 12 daily doses of 2 Gy γ-rays over a 19-day period.
Key experimental techniques included comparing low-LET γ-rays ($^{137}$Cs) with high-LET α-particles ($^{241}$Am). Molecular changes were tracked using RT-qPCR and Western blotting, focusing on DAB2IP and DNA Damage Response (DDR) markers like ATM, ATR, and DNA-PKcs. Radiosensitivity was assessed through colony formation assays (CFA).
Results and Discussion
Treatment-Induced Gene Suppression
A critical finding was that fractionated radiation progressively reduces DAB2IP expression. As shown in Figure 3B, mRNA levels dropped continuously through the 12-fraction cycle, reaching their lowest point at the end of the treatment period. This suggests that the treatment itself may drive the development of a more resistant cellular phenotype by selecting for or inducing DAB2IP loss.
Divergent Resistance Mechanisms
The loss of DAB2IP re-wires the cellular response to DNA damage differently depending on the radiation type:
- Against γ-rays: Resistance is primarily mediated by the ATM pathway. Irradiation induced a significant increase in ATM mRNA in DAB2IP-deficient cells (Figure 3C).
- Against α-particles: Resistance appears driven by the ATR pathway. While α-particles were significantly more effective than γ-rays overall (Relative Biological Effectiveness of ~9-11), shDAB2IP cells still exhibited significantly higher survival rates than controls when hit with high-LET radiation.
Therapeutic Implications
Inhibiting ATM with the specific inhibitor KU55933 successfully sensitized cells to γ-rays but failed to improve the response to α-particles in DAB2IP-deficient cells. This shift to ATR-dependency for high-LET radiation suggests that combining α-particle therapy with ATR inhibitors might be a more potent strategy to overcome acquired radioresistance.
Conclusion
This study demonstrates that radiotherapy can induce the downregulation of the tumor suppressor DAB2IP, leading to acquired radioresistance in prostate cancer. While α-particles offer a powerful alternative, DAB2IP deficiency provides a survival advantage even against high-LET radiation. Future clinical strategies may need to incorporate ATR inhibitors alongside advanced radiation therapies to effectively target these resistant cell populations.
Summary updated